Methylphenidate

Centrally acting psychostimulant

ATC code: N06BA04

Updated 26 May 2026 · Methodology

Indications

ADHD

First line

First-line for attention-deficit hyperactivity disorder in children over 6 and adults per 2019, NG87 (2018), and the Spanish SEPyP 2024 consensus. Children start at 5 mg 1–2 times daily; adults at 18 mg (Concerta) once daily in the morning. Cortese 2018 meta-analysis showed efficacy 0.78 SMD on ADHD symptoms in children. Mandatory pre-treatment psychiatric assessment, cardiovascular risk evaluation (ECG, BP, arrhythmia family history), and baseline growth and weight. Reassessment every 3–6 months.

Sources

ICD-10: F90.0 · ICD-11: 6A05

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

Memory and concentration enhancement

Not recommended

Methylphenidate is a psychostimulant prescribed for attention-deficit/hyperactivity disorder (ADHD) in children over 6 and adults, and for narcolepsy ( 2019 and AAFP 2020 guidelines). Healthy students, programmers, and knowledge workers often take methylphenidate as a cognitive stimulant. The Repantis 2010 meta-analysis showed only a minimal effect on working memory and attention in healthy adults, far less than in genuine ADHD. Methylphenidate is a Schedule II controlled substance in the US because of high abuse potential. Use carries risks of hypertension, tachycardia, insomnia, appetite loss, anxiety, psychosis at high doses, and dependence. If methylphenidate is being taken for work concentration outside an ADHD indication, consider seeking a second opinion.

Sources

How to read tiers A–F

AStrong evidence – first or second line in international guidelines
BRecommended in selected cases
CStudy data contradict each other
DBenefit not proven, no documented harm
FDocumented harm, or risk without benefit

Mechanism of action

A presynaptic noradrenaline and dopamine reuptake inhibitor. Raises catecholamine concentration in prefrontal cortex synapses, improving attention, focus, and impulse control in ADHD patients. Structurally differs from amphetamines by less neurotransmitter release induction – lower abuse potential but still a controlled substance. Half-life 2–3 hours immediate-release; 8–12 hours OROS form (Concerta). In Spain prescribed only by specialists (psychiatrist or pediatrician).

Safety

Boxed warning

FDA boxed warning: high abuse and dependence potential. Schedule II controlled substance (US), narcotic list in Spain. Not prescribed to patients with history of stimulant abuse or family history of dependence.

Contraindications

Methylphenidate hypersensitivity
Severe hypertension, hyperthyroidism, pheochromocytoma
Cardiovascular disease (angina, arrhythmias, cardiomyopathy, congenital heart defects)
Glaucoma
Psychotic disorders, severe depression, bipolar disorder (manic switch risk)
Anorexia or bulimia
Tics, Tourette syndrome
Age under 6
Concurrent MAO inhibitors or within 14 days of stopping
Pregnancy and lactation

Serious adverse effects

Cardiovascular events (sudden cardiac death, MI, stroke)
Psychotic episodes and hallucinations
Manic episodes in undiagnosed bipolar disorder
Tics (new or worsening)
Serotonin syndrome with SSRIs
Growth retardation in children with long-term use
Priapism (rare)

Common adverse effects

Reduced appetite and weight loss
Insomnia
Headache
Anxiety and irritability
Tachycardia and BP elevation
Dry mouth
Abdominal pain

Pregnancy: can you take Methylphenidate?

Methylphenidate crosses the placenta. T1 use linked to a small increase in cardiac defect risk. T3 – neonatal withdrawal risk. Pregnancy use not recommended without clear indication.

Breastfeeding: can you take Methylphenidate?

Milk concentrations are low, but infant insomnia and reduced weight gain are described. Use during lactation cautiously with monitoring of infant sleep and weight gain.

RID, infant dose via milk: 0.2%

Calculate RID Full profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Common myths

Myth: «methylphenidate is a safe cognitive enhancer for students and knowledge workers without ADHD.» Fact: in healthy people without ADHD, methylphenidate does not improve learning or memory (Repantis 2010 meta-analysis) but raises the risk of dependence (especially with snorting or injection), cardiovascular events, and psychotic episodes. In Spain, the US, and the UK, unauthorized «for studying» use is a serious risk; it spreads via prescription-free channels where the drug is often counterfeit. Myth: «methylphenidate in children causes adult addiction.» Fact: the Wilens 2003 meta-analysis showed adequate ADHD therapy with methylphenidate lowers adult substance abuse risk, not raises. Untreated ADHD is itself a dependence risk factor.

Drug–drug interactions

1 pair found. Sorted from critical to minor.

ModerateAtomoxetineCentrally acting sympathomimetics

Mechanism

Methylphenidate blocks the reuptake of noradrenaline and dopamine (methylphenidate summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Atomoxetine selectively blocks the noradrenaline transporter (atomoxetine SmPC, AEMPS). Both drugs raise blood pressure and heart rate, so the SmPCs of both ask for caution with other drugs that raise blood pressure. The atomoxetine SmPC also warns of possible synergistic or additive effects with drugs that act on noradrenaline (SmPCs of both drugs, AEMPS). In a study, giving atomoxetine with methylphenidate did not increase cardiovascular effects beyond those seen with methylphenidate alone (atomoxetine label, US Food and Drug Administration, ). No pharmacokinetic interaction is expected. Cytochrome P450 (CYP) enzymes play no clinically relevant part in methylphenidate metabolism, and methylphenidate does not inhibit them to a relevant extent (methylphenidate SmPC, AEMPS). Atomoxetine causes no clinically important inhibition or induction of the main CYP enzymes (atomoxetine FDA label).

Symptoms

In most people, heart rate and blood pressure rise moderately. With central nervous system stimulants, including methylphenidate, blood pressure rises by about 2–4 mm Hg and heart rate by about 3–6 beats per minute on average (methylphenidate label, US Food and Drug Administration, ). With atomoxetine, heart rate rises on average by less than 10 beats per minute and blood pressure by less than 5 mm Hg (atomoxetine summary of product characteristics, SmPC). Some people have larger rises. With atomoxetine, 8–12% of children and adolescents and 6–10% of adults had heart rate increases of 20 beats per minute or more and blood pressure increases of 15–20 mm Hg or more (atomoxetine SmPC). Palpitations, chest pain on exertion, unexplained fainting and shortness of breath can point to heart disease (atomoxetine SmPC).

Management

Use the combination with caution. The summaries of product characteristics (SmPCs) of both drugs ask for caution with other drugs that raise blood pressure. The atomoxetine SmPC also asks for caution with drugs that act on noradrenaline (methylphenidate and atomoxetine SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). In a study, atomoxetine did not add to the cardiovascular effects of methylphenidate, and the documents set no dose adjustment for this pair (atomoxetine label, US Food and Drug Administration, ). Before starting each drug, take a detailed history and examine the patient to look for heart disease (SmPCs of both drugs, AEMPS). Record pulse and blood pressure before treatment, after each dose change and then at least every 6 months (SmPCs of both drugs, AEMPS). If blood pressure rises markedly, review the atomoxetine treatment or the other drug that raises blood pressure (atomoxetine SmPC, AEMPS). Stop methylphenidate in case of recurrent tachycardia, arrhythmia or systolic blood pressure above the 95th percentile, and consider referral to a cardiologist (methylphenidate SmPC, AEMPS). If palpitations, chest pain on exertion, unexplained fainting or shortness of breath occur, refer the patient promptly to a cardiologist (atomoxetine SmPC, AEMPS). Both SmPCs count a concomitant drug that raises blood pressure as a risk factor for cerebrovascular events, so check for neurological signs and symptoms at every visit (SmPCs of both drugs, AEMPS).

Sources

Pair details →Atomoxetine →

Label mentions29 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

CriticalMAO inhibitorsclass named in the label
«Monoamine Oxidase Inhibitors: Methylphenidate transdermal system is contraindicated during treatment with monoamine oxidase inhibitors, and within a minimum of 14 days following discontinuation of…»
FDA, section 4 · Open on DailyMed
Moderateanticoagulantesclass named in the label
«Interacción farmacocinética: Sin embargo, se han notificado casos que indican que el metilfenidato puede inhibir el metabolismo de los anticoagulantes cumarínicos, los anticonvulsivantes (por…»
AEMPS, section 4.5 · Open on CIMA
Moderateanticoagulantsclass named in the label
«Coumarin Anticoagulants, Antidepressants, and Selective Serotonin Reuptake Inhibitors: Human pharmacologic studies have shown that methylphenidate may inhibit the metabolism of coumarin…»
FDA, section 7 · Open on DailyMed
Moderateantidepresivos tricíclicosclass named in the label
«Interacción farmacocinética: Sin embargo, se han notificado casos que indican que el metilfenidato puede inhibir el metabolismo de los anticoagulantes cumarínicos, los anticonvulsivantes (por…»
AEMPS, section 4.5 · Open on CIMA
Moderateantiepilépticosclass named in the label
«Interacción farmacocinética: Sin embargo, se han notificado casos que indican que el metilfenidato puede inhibir el metabolismo de los anticoagulantes cumarínicos, los anticonvulsivantes (por…»
AEMPS, section 4.5 · Open on CIMA
Moderateantiepilepticsclass named in the label
«Coumarin Anticoagulants, Antidepressants, and Selective Serotonin Reuptake Inhibitors: Human pharmacologic studies have shown that methylphenidate may inhibit the metabolism of coumarin…»
FDA, section 7 · Open on DailyMed
Moderateantipsicóticosclass named in the label
«Uso con fármacos dopaminérgicos: Se recomienda precaución al administrar metilfenidato con fármacos dopaminérgicos, incluyendo antipsicóticos. Dado que una de las principales acciones de…»
AEMPS, section 4.5 · Open on CIMA
ModerateISRSclass named in the label
«Interacción farmacocinética: Sin embargo, se han notificado casos que indican que el metilfenidato puede inhibir el metabolismo de los anticoagulantes cumarínicos, los anticonvulsivantes (por…»
AEMPS, section 4.5 · Open on CIMA
ModeratePhenobarbital
«Interacción farmacocinética: Sin embargo, se han notificado casos que indican que el metilfenidato puede inhibir el metabolismo de los anticoagulantes cumarínicos, los anticonvulsivantes (por…»
AEMPS, section 4.5 · Open on CIMA
ModeratePhenobarbital
«Coumarin Anticoagulants, Antidepressants, and Selective Serotonin Reuptake Inhibitors: Human pharmacologic studies have shown that methylphenidate may inhibit the metabolism of coumarin…»
FDA, section 7 · Open on DailyMed
ModeratePhenytoin
«Interacción farmacocinética: Sin embargo, se han notificado casos que indican que el metilfenidato puede inhibir el metabolismo de los anticoagulantes cumarínicos, los anticonvulsivantes (por…»
AEMPS, section 4.5 · Open on CIMA
ModeratePhenytoin
«Coumarin Anticoagulants, Antidepressants, and Selective Serotonin Reuptake Inhibitors: Human pharmacologic studies have shown that methylphenidate may inhibit the metabolism of coumarin…»
FDA, section 7 · Open on DailyMed
ModerateRisperidone
«Risperidone: Combined use of methylphenidate with risperidone when there is a change in dosage, whether an increase or decrease, of either or both medications, may increase the risk of extrapyramidal…»
FDA, section 7 · Open on DailyMed
ModerateSSRIs/SNRIsclass named in the label
«Coumarin Anticoagulants, Antidepressants, and Selective Serotonin Reuptake Inhibitors: Human pharmacologic studies have shown that methylphenidate may inhibit the metabolism of coumarin…»
FDA, section 7 · Open on DailyMed
Moderatetricyclic antidepressantsclass named in the label
«Coumarin Anticoagulants, Antidepressants, and Selective Serotonin Reuptake Inhibitors: Human pharmacologic studies have shown that methylphenidate may inhibit the metabolism of coumarin…»
FDA, section 7 · Open on DailyMed
Clonidine
«Uso con agonistas alfa-2 de acción central (por ejemplo clonidina): Se han notificado acontecimientos adversos graves, incluida la muerte súbita, con el uso concomitante de metilfenidato y clonidina…»
AEMPS, section 4.5 · Open on CIMA
medicamentos serotoninérgicosclass named in the label
«Uso con medicamentos serotoninérgicos: Se han notificado casos de síndrome serotoninérgico tras la coadministración de metilfenidato con medicamentos serotoninérgicos. Si se justifica el uso…»
AEMPS, section 4.5 · Open on CIMA

From other drugs’ labels

CriticalPhenelzine
«CONTRAINDICATIONS: The potentiation of sympathomimetic substances and related compounds by MAO inhibitors may result in hypertensive crises (see WARNINGS ). Therefore, patients being treated with…»
FDA, section 4 · Open on DailyMed
CriticalPimozide
«CONTRAINDICATIONS: Pimozide should not be used in patients taking drugs that may, themselves, cause motor and phonic tics (e.g., pemoline, methylphenidate and amphetamines) until such patients have…»
FDA, section 4 · Open on DailyMed
CriticalTranylcypromine
«Combination with Certain Drugs: Amphetamines and methylphenidates and derivatives»
FDA, section 4 · Open on DailyMed
MajorClonidine
«Insuficiencia renal: Catapresan no está recomendado para uso en niños y adolescentes debido a la escasez de datos sobre seguridad y eficacia. En particular, cuando clonidina se utiliza fuera de las…»
AEMPS, section 4.4 · Open on CIMA
ModerateAmitriptyline
«Potencial de otros medicamentos para afectar a la amitriptilina: Otros inhibidores del citocromo P450 : La cimetidina, el metilfenidato y los antagonistas de los canales del calcio (p. ej…»
AEMPS, section 4.5 · Open on CIMA
ModerateHydralazine
«Uso concomitante que requiere ajuste posológico: Metilfenidato: el uso simultáneo puede disminuir su efecto antihipertensivo.»
AEMPS, section 4.5 · Open on CIMA
ModeratePaliperidone
«Discinesia tardía/síntomas extrapiramidales: Se requiere precaución en pacientes que reciben tanto psicoestimulantes (p. ej., metilfenidato) como paliperidona de forma concomitante, ya que pueden…»
AEMPS, section 4.4 · Open on CIMA
ModerateRisperidone
«Discinesia tardía/síntomas extrapiramidales (DT/SEP): Se requiere precaución en pacientes que reciben tanto psicoestimulantes (p. ej., metilfenidato) como risperidona de forma concomitante, ya que…»
AEMPS, section 4.4 · Open on CIMA
ModerateRisperidone
«Pharmacodynamic-related Interactions: Concomitant use with methylphenidate, when there is change in dosage of either medication, may increase the risk of extrapyramidal symptoms (EPS). Monitor for…»
FDA, section 7 · Open on DailyMed
MinorAtomoxetine
«Methylphenidate: Coadministration of methylphenidate with atomoxetine did not increase cardiovascular effects beyond those seen with methylphenidate alone.»
FDA, section 7 · Open on DailyMed
Brimonidine
«clorpromazina, metilfenidato, reserpina.»
AEMPS, section 4.5 · Open on CIMA
Phenytoin
«Drugs that Affect Phenytoin Concentrations: Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines…»
FDA, section 7 · Open on DailyMed

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Methylphenidate used for?

Methylphenidate is evaluated for the following indications with varying evidence strength: ADHD (evidence tier A), Memory and concentration enhancement (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Methylphenidate?

Common side effects of Methylphenidate (≥ 1 in 100): Reduced appetite and weight loss, Insomnia, Headache, Anxiety and irritability, Tachycardia and BP elevation, Dry mouth. See the Safety section for uncommon and serious reactions.

Is Methylphenidate safe during pregnancy?

Methylphenidate crosses the placenta. T1 use linked to a small increase in cardiac defect risk. T3 – neonatal withdrawal risk. Pregnancy use not recommended without clear indication.

Is Methylphenidate compatible with breastfeeding?

Milk concentrations are low, but infant insomnia and reduced weight gain are described. Use during lactation cautiously with monitoring of infant sleep and weight gain.

Who should not take Methylphenidate?

Methylphenidate is contraindicated in: Methylphenidate hypersensitivity; Severe hypertension, hyperthyroidism, pheochromocytoma; Cardiovascular disease (angina, arrhythmias, cardiomyopathy, congenital heart defects); Glaucoma; Psychotic disorders, severe depression, bipolar disorder (manic switch risk). Full list in the Safety section.

Does Methylphenidate carry an FDA boxed warning?

Official sources

Direct links to regulator labels. Open in a new tab.

AEMPS / CIMALabel dated 06/01/2026
FDA / DailyMedLabel dated 10/07/2025

Other drugs in this group

Mirtazapine, Moclobemide, Noopept (N-phenylacetyl-L-prolylglycine ethyl ester), Paroxetine, Picamilon (nicotinoyl-GABA), Venlafaxine, Caffeine, Fluvoxamine